Published in Gastroenterology on December 19, 2016
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
Liver regeneration. Science (1997) 12.80
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Role of YAP/TAZ in mechanotransduction. Nature (2011) 11.56
The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell (2005) 10.61
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol (2007) 8.11
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell (2003) 7.43
Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell (2009) 7.39
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell (2012) 6.80
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature (1993) 6.67
Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol (2004) 6.36
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell (2003) 5.66
The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Dev Cell (2008) 5.58
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev (2010) 5.38
Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin. Cell (2001) 5.01
Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A (2010) 4.95
The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. Dev Cell (2008) 4.90
Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell (2011) 4.85
A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J (1999) 4.66
Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61
TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J (2000) 4.55
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev (2012) 4.19
Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A (2010) 4.17
Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev (2010) 3.77
Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. Am J Pathol (2009) 3.55
Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature (2012) 3.54
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
SCALLOPED interacts with YORKIE, the nuclear effector of the hippo tumor-suppressor pathway in Drosophila. Curr Biol (2008) 3.39
The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Dev (2003) 3.32
The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A (2010) 3.18
A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell (2013) 3.17
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev (2011) 3.15
Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol (2006) 3.15
Notch signaling controls liver development by regulating biliary differentiation. Development (2009) 2.93
YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol (2014) 2.93
Self-renewing diploid Axin2(+) cells fuel homeostatic renewal of the liver. Nature (2015) 2.77
YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol (2012) 2.59
YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev (2009) 2.58
Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem (2011) 2.47
Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. Dev Cell (2006) 2.45
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
The cholangiopathies: disorders of biliary epithelia. Gastroenterology (2004) 2.38
Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci U S A (2007) 2.31
Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. Am J Physiol Renal Physiol (2008) 2.24
Hippo pathway activity influences liver cell fate. Cell (2014) 2.24
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet (2015) 2.17
Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell (2013) 2.16
Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Cancer Res (2009) 2.05
Angiomotin-like proteins associate with and negatively regulate YAP1. J Biol Chem (2010) 1.95
The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene (2011) 1.95
Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol (2010) 1.91
Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. Chem Biol (2012) 1.91
Hybrid Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise to Cancer. Cell (2015) 1.89
Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev (2012) 1.86
A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell (2011) 1.86
Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology (2014) 1.84
Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome. Development (2010) 1.78
Links between alpha-catenin, NF-kappaB, and squamous cell carcinoma in skin. Proc Natl Acad Sci U S A (2006) 1.77
Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res (2010) 1.77
MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1. Nat Commun (2013) 1.76
Transcriptional coactivation of bone-specific transcription factor Cbfa1 by TAZ. Mol Cell Biol (2003) 1.69
A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell (2014) 1.68
The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex. Dev Cell (2010) 1.67
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology (2013) 1.58
LKB1 tumor suppressor protein: PARtaker in cell polarity. Trends Cell Biol (2004) 1.57
Enhanced liver regeneration following changes induced by hepatocyte-specific genetic ablation of integrin-linked kinase. Hepatology (2009) 1.54
IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology (2015) 1.52
A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nat Cell Biol (2013) 1.41
Emerging roles of Notch signaling in liver disease. Hepatology (2014) 1.39
Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol (2015) 1.39
A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell (1993) 1.38
Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology (2012) 1.34
Cholangiocyte proliferation and liver fibrosis. Expert Rev Mol Med (2009) 1.32
Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int (2011) 1.31
TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function. Mol Cell (2013) 1.29
The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Sci Signal (2013) 1.25
Alternative Wnt Signaling Activates YAP/TAZ. Cell (2015) 1.21
Role of Lgl/Dlg/Scribble in the regulation of epithelial junction, polarity and growth. Front Biosci (2008) 1.21
VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res (2014) 1.20
The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver zonation and size. Nat Cell Biol (2016) 1.16
Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice. J Clin Invest (2012) 1.16
Yes-associated protein regulates the hepatic response after bile duct ligation. Hepatology (2012) 1.15
Bile acids activate YAP to promote liver carcinogenesis. Cell Rep (2013) 1.14
A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis. Genes Dev (2015) 1.13
Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP. Genes Dev (2015) 1.12
YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. Cell Rep (2015) 1.08
Challenges to liver transplantation and strategies to improve outcomes. Gastroenterology (2014) 1.05
Wnt signaling and hepatocarcinogenesis: the hepatoblastoma model. Int J Biochem Cell Biol (2009) 1.05
YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers. Mol Cell (2015) 1.04
Split liver transplantation: an overview. Transplant Proc (2011) 1.02
The Ets transcription factor GABP is a component of the hippo pathway essential for growth and antioxidant defense. Cell Rep (2013) 1.01
LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap. Oncogene (2012) 1.00
Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration. Am J Physiol Gastrointest Liver Physiol (2014) 0.96
YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors. Hepatology (2015) 0.96
Differences in Yes-associated protein and mRNA levels in regenerating liver and hepatocellular carcinoma. Mol Med Rep (2011) 0.95